Literature DB >> 9186482

NADH oxidase activity from sera altered by capsaicin is widely distributed among cancer patients.

D J Morré1, S Caldwell, A Mayorga, L Y Wu, D M Morré.   

Abstract

A cancer-specific form of NADH oxidase inhibited or stimulated by 1 or 100 microM capsaicin (8-methyl-N-vanillyl-6-noneamide) is present in sera from cancer patients. The capsaicin-inhibited NADH oxidase activity appears to be absent from sera of individuals free of cancer. The capsaicin-inhibited activity is present both in freshly collected sera and in sera stored frozen for varying periods of time. For the latter, an assay was carried out under renaturing conditions in the presence of NADH and reduced glutathione followed by dilute hydrogen peroxide. Inhibition was half maximal at about 1 microM capsaicin. The capsaicin-inhibited activity was found in sera over a broad spectrum of cancer patients including patients with solid cancers (e.g., breast, prostate, lung, ovarian) as well as with leukemias and lymphomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186482     DOI: 10.1006/abbi.1997.0110

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  10 in total

1.  Essential role of copper in the activity and regular periodicity of a recombinant, tumor-associated, cell surface, growth-related and time-keeping hydroquinone (NADH) oxidase with protein disulfide-thiol interchange activity (ENOX2).

Authors:  Xiaoyu Tang; P-J Chueh; Ziying Jiang; Sara Layman; Berdine Martin; Chinpal Kim; Dorothy M Morré; D James Morré
Journal:  J Bioenerg Biomembr       Date:  2010-10-05       Impact factor: 2.945

2.  Association between NADPH oxidase (NOX) and lung cancer: a systematic review and meta-analysis.

Authors:  Ming Han; Tianhui Zhang; Lei Yang; Zitong Wang; Junzhong Ruan; Xiujun Chang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 3.  An updated review on molecular mechanisms underlying the anticancer effects of capsaicin.

Authors:  Seok-Cheol Cho; Hyosung Lee; Bu Young Choi
Journal:  Food Sci Biotechnol       Date:  2017-02-28       Impact factor: 2.391

4.  hnRNP F directs formation of an exon 4 minus variant of tumor-associated NADH oxidase (ENOX2).

Authors:  Xiaoyu Tang; Vanessa D Kane; Dorothy M Morré; D James Morré
Journal:  Mol Cell Biochem       Date:  2011-05-28       Impact factor: 3.396

Review 5.  Update on a tumor-associated NADH oxidase in gastric cancer cell growth.

Authors:  Hsiao-Ling Cheng; Yi-Hui Lee; Tein-Ming Yuan; Shi-Wen Chen; Pin-Ju Chueh
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

6.  Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin.

Authors:  Laurent Schwartz; Adeline Guais; Maurice Israël; Bernard Junod; Jean-Marc Steyaert; Elisabetta Crespi; Gianfranco Baronzio; Mohammad Abolhassani
Journal:  Invest New Drugs       Date:  2012-07-14       Impact factor: 3.850

7.  Benzo[b]thiophenesulphonamide 1,1-dioxide derivatives inhibit tNOX activity in a redox state-dependent manner.

Authors:  I Encío; D J Morré; R Villar; M J Gil; V Martínez-Merino
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

8.  Tumor-associated NADH oxidase (tNOX)-NAD+-sirtuin 1 axis contributes to oxaliplatin-induced apoptosis of gastric cancer cells.

Authors:  Huei-Yu Chen; Hsiao-Ling Cheng; Yi-Hui Lee; Tien-Ming Yuan; Shi-Wen Chen; You-Yu Lin; Pin Ju Chueh
Journal:  Oncotarget       Date:  2017-02-28

9.  Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.

Authors:  Huei-Yu Chen; Atikul Islam; Tien-Ming Yuan; Shi-Wen Chen; Pei-Fen Liu; Pin Ju Chueh
Journal:  J Exp Clin Cancer Res       Date:  2018-07-20

10.  ENOX2 target for the anticancer isoflavone ME-143.

Authors:  D James Morré; Theodore Korty; Christiaan Meadows; Laura M C Ades; Dorothy M Morré
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.